<DOC>
	<DOC>NCT01234597</DOC>
	<brief_summary>Primary Objective: To evaluate the effect of prandial treatment adjustment, based on continuous blood glucose monitoring, on glucose control in type 2 diabetes patients who are not controlled by treatment with once daily basal insulin or mixed insulin, requiring treatment with basal plus regimen</brief_summary>
	<brief_title>Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day</brief_title>
	<detailed_description>The study duration for each patient is 24 weeks +/- 1 week broken down as follows: - Run-in phase: 8 weeks - Follow - up Period: 16 weeks The maximal possible time window during the study is +/- one week throughout the study.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criteria: Runin period: 1. Type 2 diabetes 2. HbA1câ‰¥ 8.5% (in a test of the last month) 3. Age above 21 years 4. Patients continuously treated with basal insulin or mixed insulin once daily for the last 6 months 5. Signed informed consent form 6. Patients who according to their physician are eligible to the study Randomization: 1. HbA1c &gt; 7.5% 2. FPG &lt; 130 mg/dl Exclusion criteria: 1. Type 1 diabetes 2. Patients continuously treated with shortacting insulin or mixed insulin more than once daily for 3 weeks during the last 6 months. 3. Pregnant or breastfeeding women. 4. Patients with allergy to insulin. 5. Patients with severe diseases characterized by recurrent hospitalizations, including: Severe renal insufficiency, severe cardiac insufficiency, active oncological disease or oncological disease requiring chemotherapy. 6. Patients with mobility difficulties and/or difficulties communicating with the investigator The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>